Literature DB >> 20333679

Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis.

Dana Briesemeister1, Daniel Sommermeyer, Christoph Loddenkemper, Rainer Loew, Wolfgang Uckert, Thomas Blankenstein, Thomas Kammertoens.   

Abstract

It has been shown that injecting a suspension of IFN-γ-secreting tumor cells results in their rejection. This effect has been attributed to IFN-γ preventing tumor stroma formation but not to a direct effect on the cancer cells. However, it is not known, which influence IFN-γ has on tumors with an established stroma. To address this question, the plasmacytoma cell line J558L was transduced with a vector allowing doxycycline-inducible IFN-γ gene expression. After the injection of the tumor cells into mice, IFN-γ was induced at different time points. Tumors did not grow when inducing IFN-γ immediately after tumor cell inoculation, while approximately half of the tumors were rejected when IFN-γ was induced in early established tumors within 2 weeks. Induction of IFN-γ 2-3 weeks after tumor cell inoculation was less efficient (0-17% rejection). IFN-γ induction in established tumors led to a reduction of CD146(+) endothelial cells and massive necrosis. Together, we show that vascularized tumors can be rejected by local IFN-γ expression, but that rejection of established tumors was less efficient over time. This suggests that transplanted tumors became less susceptible to local IFN-γ treatment the better they are established.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20333679     DOI: 10.1002/ijc.25350

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.

Authors:  Thomas Kammertoens; Christian Friese; Ainhoa Arina; Christian Idel; Dana Briesemeister; Michael Rothe; Andranik Ivanov; Anna Szymborska; Giannino Patone; Severine Kunz; Daniel Sommermeyer; Boris Engels; Matthias Leisegang; Ana Textor; Hans Joerg Fehling; Marcus Fruttiger; Michael Lohoff; Andreas Herrmann; Hua Yu; Ralph Weichselbaum; Wolfgang Uckert; Norbert Hübner; Holger Gerhardt; Dieter Beule; Hans Schreiber; Thomas Blankenstein
Journal:  Nature       Date:  2017-04-26       Impact factor: 49.962

2.  Immunoregulation effects of bone marrow-derived mesenchymal stem cells in xenogeneic acellular nerve grafts transplant.

Authors:  Lihong Fan; Zefeng Yu; Jia Li; Xiaoqian Dang; Kunzheng Wang
Journal:  Cell Mol Neurobiol       Date:  2014-06-17       Impact factor: 5.046

3.  Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer.

Authors:  Kathleen Anders; Christian Buschow; Andreas Herrmann; Ana Milojkovic; Christoph Loddenkemper; Thomas Kammertoens; Peter Daniel; Hua Yu; Jehad Charo; Thomas Blankenstein
Journal:  Cancer Cell       Date:  2011-12-13       Impact factor: 31.743

4.  UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer.

Authors:  Bingbing Wu; Mei Song; Qun Dong; Gang Xiang; Jing Li; Xiaojing Ma; Fang Wei
Journal:  Theranostics       Date:  2022-07-04       Impact factor: 11.600

5.  Fas expression by tumor stroma is required for cancer eradication.

Authors:  Joanna J Listopad; Thomas Kammertoens; Kathleen Anders; Bjoern Silkenstedt; Gerald Willimsky; Karin Schmidt; Anja A Kuehl; Christoph Loddenkemper; Thomas Blankenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

6.  CD8 engineered cytotoxic T cells reprogram melanoma tumor environment.

Authors:  Julie Leignadier; Stephanie Favre; Sanjiv A Luther; Immanuel F Luescher
Journal:  Oncoimmunology       Date:  2015-09-11       Impact factor: 8.110

7.  Immunosurveillance by antiangiogenesis: tumor growth arrest by T cell-derived thrombospondin-1.

Authors:  Keri L Schadler; Erika J Crosby; Alice Yao Zhou; Dong Ha Bhang; Lior Braunstein; Kwan Hyuck Baek; Danielle Crawford; Alison Crawford; Jill Angelosanto; E John Wherry; Sandra Ryeom
Journal:  Cancer Res       Date:  2014-03-03       Impact factor: 12.701

Review 8.  Anti-cancer therapy with TNFα and IFNγ: A comprehensive review.

Authors:  Jing Shen; Zhangang Xiao; Qijie Zhao; Mingxing Li; Xu Wu; Lin Zhang; Wei Hu; Chi H Cho
Journal:  Cell Prolif       Date:  2018-02-26       Impact factor: 6.831

9.  Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium.

Authors:  David C Binder; Ainhoa Arina; Frank Wen; Tony Tu; Ming Zhao; Robert M Hoffman; Derek A Wainwright; Hans Schreiber
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

10.  Rapid Depletion of Intratumoral Regulatory T Cells Induces Synchronized CD8 T- and NK-cell Activation and IFNγ-Dependent Tumor Vessel Regression.

Authors:  Yutaka Kurebayashi; Colleen P Olkowski; Kelly C Lane; Olga V Vasalatiy; Biying C Xu; Ryuhei Okada; Aki Furusawa; Peter L Choyke; Hisataka Kobayashi; Noriko Sato
Journal:  Cancer Res       Date:  2021-02-11       Impact factor: 13.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.